3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
30
Neoplasms
11
Thyroid Neoplasms
7
Thyroid Carcinoma, Anaplastic
6
Brain Neoplasms
6
Multiple Myeloma
4
Glioma
4
Colorectal Neoplasms
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Cancer, Papillary
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Glioblastoma
2
Astrocytoma
2
Ameloblastoma
2
Adenocarcinoma, Follicular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Rectal Neoplasms
1
Rare Malignant Neoplasm
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
dabrafenib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled